PROSPECTUS SUPPLEMENT Filed pursuant to Rule 424(b)(3)
To Prospectus Dated January 14, 1998, Registration No. 333-38995
As Supplemented to Date
5,204,305 Shares
PHYMATRIX CORP.
Common Stock
-------------
This Prospectus Supplement relates to the resale by certain stockholders of
shares of PhyMatrix Corp. Common Stock under PhyMatrix's Registration Statement
on Form S-3 (SEC File No. 333-38995). The Prospectus that is a part of the
Registration Statement was originally filed with the Securities and Exchange
Commission on January 15, 1998. You should read this Supplement with the
Prospectus, as supplemented to date, which is being delivered with this
Supplement. Capitalized terms used and not defined in this Supplement have the
meanings given to them in the Prospectus.
Based on information provided to PhyMatrix by the Selling Stockholders
listed below, the following Selling Stockholders may sell the number of shares
opposite their respective names pursuant to this Prospectus, as supplemented to
date. To the best of our knowledge, the shares listed below represent all the
shares of Common Stock owned by such Selling Stockholders.
<TABLE>
<CAPTION>
Number of
Selling Stockholder Shares
<S> <C>
The WAB Family Limited Partnership(1) 1,655,756
Beverly Austin(2) 250
Donald Austin, Sr.(2) 250
Mr. and Mrs. Donald Austin, Jr.(2) 250
Julie Austin(2) 250
Mr. and Mrs. Henry Heffernan(2) 250
Mr. and Mrs. Kevin Heffernan(2) 250
Michael T. Heffernan(3) 314,793
Shaun Heffernan(2) 250
Mr. and Mrs. Todd Pelazza(2) 250
</TABLE>
- ----------------
(1) Walter A. Brown is the sole limited and general partner of the limited
partnership. Dr. Brown served as a director and secretary of Clinical
Studies, Ltd. from 1990 until Clinical Studies, Ltd. was acquired by
PhyMatrix in October 1997. The shares were issued to Dr. Brown in
connection with that acquisition. Based on information provided by the
stockholder to PhyMatrix, upon the sale of such shares, The WAB Family
Limited Partnership will hold no shares of PhyMatrix after the offering of
such shares.
(2) Each of the noted stockholders is related by either blood or marriage to
Michael T. Heffernan, a director of PhyMatrix and President of its
subsidiary Clinical Studies, Ltd. Based on information provided by such
stockholders to PhyMatrix, upon the sale of such shares, none of the
stockholders will hold any shares of PhyMatrix.
(3) Mr. Heffernan also holds an option to purchase 300,000 shares of PhyMatrix
Common Stock. Such option shares are not subject to this Prospectus. If,
after this offering, the option is exercised, such shares will constitute
less than 1% of PhyMatrix's outstanding Common Stock. Mr. Heffernan has
served as President of Clinical Studies, Ltd. since January 1994. He has
served as a director of PhyMatrix since February 1998.
Additional information concerning other Selling Stockholders and other
matters is set forth in the original Prospectus. We encourage you to read the
entire Prospectus as supplemented to date.
On October 12, 1998, the closing price reported for such shares on Nasdaq
was $2.25.
The date of this Prospectus Supplement is October 14, 1998.
